71616
83942
85186
85872;Glucose Tolerance Test
214657;In Vitro Techniques
314074
323461;Fasting;Models, Biological;Clinical Trials as Topic
363052;Double-Blind Method;Administration, Oral;Clinical Trials as Topic
406701
427007;Fasting
438273
445958
463881
496127
501875
512843;Fasting
520399
558210;Methods
564228
569766
571023
581516;Administration, Oral
589392
637437
647881
665675
758247;Diet
780287;Fasting;Models, Biological;Clinical Trials as Topic
838114;Metabolic Clearance Rate
872490
872491;Administration, Oral
970990;Fasting;Administration, Oral
991535;Diet;Metabolic Clearance Rate
1036443;Reflex;Methods
1167931
1195132;Reaction Time
1215448;Reaction Time
1241098;Biological Assay
1297641;Fasting;Chromatography, High Pressure Liquid
1335461;Chromatography, Gas
1351673;Double-Blind Method;Reference Values
1404208
1424410;Blood Pressure;Single-Blind Method;Analysis of Variance;Administration, Oral;Reference Values
1468429;Fasting;Administration, Oral
1476449;Electrophoresis, Polyacrylamide Gel;Sensitivity and Specificity;Immunoblotting;Evaluation Studies as Topic
1483487;Blood Pressure;Exercise Test;Administration, Oral
1577050;Blood Pressure;Heart Rate;Analysis of Variance
1605619;Chromatography, High Pressure Liquid
1612815;Fasting
1621740;Metabolic Clearance Rate;Clinical Trials as Topic
1656742;Drug Evaluation
1662623;Administration, Oral;Drug Stability
1672944
1672990
1679514
1681621
1683458;Administration, Oral
1706804;Double-Blind Method;Administration, Oral
1748529
1752235;Injections, Intravenous;Administration, Oral;Metabolic Clearance Rate;Chromatography, High Pressure Liquid
1766062
1772462;Administration, Oral
1774159
1780961;Fasting;Administration, Oral;Intubation, Gastrointestinal
1781863;Administration, Sublingual
1797525
1912131
1914371;Blood Pressure;Heart Rate;Analysis of Variance;Double-Blind Method;Reference Values;Random Allocation;Research Design
1914375;Heart Rate;Confidence Intervals;Double-Blind Method;Reference Values;Random Allocation
1934862;Administration, Oral;Chromatography, High Pressure Liquid;Random Allocation
1934866;Blood Pressure;Heart Rate;Double-Blind Method;Infusions, Intravenous;Random Allocation
1956499
1981783;Metabolic Clearance Rate
1988422
2042654;Reference Values
2045759;Analysis of Variance;Diet
2049250
2051716;Diet
2058471
2065699
2065700
2066050;Administration, Oral
2069371;Double-Blind Method
2071262
2091623;Blood Pressure;Heart Rate
2099431;Diet
2106407
2107985;Injections, Intravenous;Perfusion;Radionuclide Imaging
2112643;Glomerular Filtration Rate;Metabolic Clearance Rate
2114955;Body Weight;Intubation, Gastrointestinal
2122025
2122422;Administration, Oral;Infusions, Intravenous
2171446;Administration, Oral
2177401;Models, Biological
2200264
2253583;Metabolic Clearance Rate;Dialysis;Chromatography, High Pressure Liquid
2271748
2285293;Chromatography, High Pressure Liquid
2311339;Fasting;Administration, Oral;Random Allocation
2338118;Radioimmunoassay;Chromatography, Gas;Random Allocation
2352608;Diet
2353062
2357862;Blood Pressure
2360879
2396245
2450251;Blood Pressure;Injections, Intravenous;Administration, Oral
2492043;Intubation, Gastrointestinal
2496251;Drug Administration Routes;Prothrombin Time
2501937
2506806;Intubation, Gastrointestinal
2510372;Random Allocation
2527534
2565585;Double-Blind Method
2580171;Blood Pressure;Heart Rate
2580172;Fasting
2589383;Infusions, Intravenous
2612087;Blood Pressure;Heart Rate
2613389;Diet;Random Allocation
2663579
2666453;Diet
2673623;Blood Pressure;Double-Blind Method;Administration, Oral;Reference Values;Clinical Trials as Topic;Random Allocation
2686430
2714732;Blood Pressure;Heart Rate
2729942
2735334
2764304
2767766;Fasting
2794993;Blood Pressure
2795213;Radionuclide Imaging;Electrocardiography
2821081
2875358
2876719
2880045
2901653
2913801
2914409
2929629;Blood Pressure;Heart Rate;Double-Blind Method;Follow-Up Studies;Electrocardiography;Random Allocation
2938522
2985676
3014110
3038451
3038494
3040815;Random Allocation
3053579
3085485;Ultrafiltration
3100311;Administration, Oral
3110450;Prothrombin Time
3116961
3121288;Administration, Oral;Random Allocation
3127188
3189445
3220610
3228106;Ultrafiltration;Drug Stability;Chromatography, High Pressure Liquid
3243931
3259827;Blood Pressure;Coronary Angiography;Heart Rate;Administration, Oral;Tomography, Emission-Computed
3278460;Fasting
3283290
3338980
3356120;Administration, Oral;Chromatography, High Pressure Liquid
3366169;Administration, Oral;Dosage Forms
3372933
3389610
3392235;Administration, Oral
3414579;Birth Weight;Regression Analysis;Body Weight;Hematocrit;Erythrocyte Count
3460737;Fasting;Random Allocation
3475034;Administration, Oral
3480885;Chromatography, High Pressure Liquid
3481318
3499163
3517081;Double-Blind Method;Clinical Trials as Topic;Random Allocation
3525654;Food Analysis;Diet
3541503;Clinical Trials as Topic
3565796
3665325
3682151
3693341
3693584;Chromatography, Gas
3720177
3734141;Breath Tests;Reaction Time;Random Allocation
3778707
3790404;Fasting
3807390;Glucose Tolerance Test
3824426;Intubation, Gastrointestinal
3838321
3838971;Administration, Oral;Metabolic Clearance Rate
3877043
3910768;Blood Pressure
3948402;Diet
3988971
3998202
3998343;Prothrombin Time
4000229;Injections, Intravenous
4003328
4005122;Administration, Oral
4006379;Fasting;Administration, Oral;Random Allocation
4014747;Injections, Intravenous;Infusions, Parenteral
4029248;Metabolic Clearance Rate
4042520;Analysis of Variance;Administration, Oral;Reaction Time;Chromatography, Gas
4064930
4099618;Fluorometry
4909796;Clinical Trials as Topic
4964450
4967225;Prothrombin Time;Methods
5104893;Prothrombin Time
5132558;Lethal Dose 50;Body Temperature
5304704
5676383
5897315;Diet;Prothrombin Time
5948152
6034391
6091711;Gastric Acidity Determination
6097665
6112560
6113376
6116064;Administration, Oral
6124334;Analysis of Variance;Double-Blind Method
6129542;Double-Blind Method;Clinical Trials as Topic;Random Allocation
6130074;Double-Blind Method
6133016
6142202
6149298
6236021
6242951;Fasting;Analysis of Variance
6282000;Administration, Oral
6285814;Chromatography, High Pressure Liquid
6322675;Fasting
6327318;Double-Blind Method
6374311;Double-Blind Method;Clinical Trials as Topic;Flicker Fusion
6389377;Blood Pressure;Heart Rate;Double-Blind Method;Random Allocation
6394124;Food Analysis;Diet
6419147
6421377
6437219
6438282
6486489;Double-Blind Method;Reaction Time;Random Allocation;Flicker Fusion
6486994
6522416
6612697;Injections, Subcutaneous
6614033;Diet
6626418;Diet
6662173;Administration, Oral;Infusions, Parenteral
6678751
6688049
6688407;Administration, Oral
6692645;Chromatography, High Pressure Liquid
6723218;Diet
6734044;Blood Pressure;Heart Rate;Administration, Oral;Chromatography, High Pressure Liquid
6734698
6741669
6786635;Glucose Tolerance Test
6794970;Blood Pressure;Injections, Intravenous;Administration, Oral
6803191;Intubation, Gastrointestinal
6806502
6807440;Injections, Intravenous;Injections, Subcutaneous
6821036
6834589
6843604;Prothrombin Time
6882312;Reaction Time
6883912;Diet
6926836
6956293
7040498
7053307;Double-Blind Method
7076627;Diet
7098543;Double-Blind Method;Flicker Fusion
7104169;Blood Pressure;Injections, Intravenous;Administration, Oral;Pulse
7105982
7118763
7174567;Fasting;Diet
7188722
7197483
7197984;Chemical Precipitation
7212893;Diet;Prothrombin Time
7237895
7270565
7274023
7308273;Blood Pressure;Heart Rate
7312071
7343191;Body Weight
7359014
7371698;Models, Biological
7383081
7406391
7454487
7486898;Prospective Studies
7551902
7582380;Cross-Over Studies;Analysis of Variance;Administration, Oral;Chemical Fractionation;Reference Values;Chromatography, High Pressure Liquid
7589032;Administration, Oral
7619679;Cross-Over Studies
7628179;Cross-Over Studies;Injections, Intravenous;Administration, Oral
7640830;Risk Factors
7648762;Cross-Over Studies;Administration, Oral;Reference Values
7677856
7697949
7715468;Cross-Over Studies;Metabolic Clearance Rate
7742162;Cross-Over Studies
7748990
7768070;Cross-Over Studies;Administration, Oral;Radioimmunoassay;Metabolic Clearance Rate;Infusions, Intravenous
7811026;Cross-Over Studies;Administration, Oral
7856583;Cross-Over Studies;Prospective Studies
7859239;Cross-Over Studies;Fasting;Double-Blind Method
7875189;Diet;Administration, Oral
7881701
7955811;Cross-Over Studies
7962690
7967987;Blood Pressure;Heart Rate;Treatment Outcome;Blood Pressure Monitoring, Ambulatory
7972311;Blood Pressure;Cross-Over Studies;Heart Rate;Chromatography, High Pressure Liquid;Spectrophotometry, Ultraviolet
7979646;Cross-Over Studies;Fasting
7990219;Fasting;Retrospective Studies
8004359;Administration, Oral;Chromatography, High Pressure Liquid
8039534;Analysis of Variance;Administration, Oral;Gastric Acidity Determination;Reference Values
8049637;Metabolic Clearance Rate
8061850;Reference Values
8064267;Fasting;Reference Values
8073064
8148213;Fasting;Chromatography, High Pressure Liquid;Infusions, Intravenous
8200332;Chromatography, High Pressure Liquid
8218972;Diet
8275614;Blood Pressure;Heart Rate
8364261;Infusions, Intravenous
8365689;Diet;Prothrombin Time
8388198;Chromatography, High Pressure Liquid
8390020
8391300;Angiography
8395986
8453178
8513655
8521677
8527268;Injections, Intravenous;Administration, Oral
8540731;Cross-Over Studies
8549357
8549360;Cross-Over Studies;Single-Blind Method
8554942;Double-Blind Method
8562295;Cross-Over Studies;Reproducibility of Results;Analysis of Variance;Linear Models
8601555
8602393;Intubation, Gastrointestinal
8607732
8612381;Prospective Studies;Electrocardiography
8617704;Diet
8631189;Cross-Over Studies;Administration, Oral;Radioimmunoassay
8642453;Food Analysis
8649594;Magnetic Resonance Imaging;Bleeding Time
8689808;Cross-Over Studies
8693526
8728348;Prospective Studies;Electroencephalography;Cohort Studies
8735685
8739026;Cross-Over Studies
8751023;Blood Pressure;Cross-Over Studies;Heart Rate
8787869;Cross-Over Studies;Intubation, Gastrointestinal
8813897
8830073;Risk Factors
8851570
8866042;Cross-Over Studies;Area Under Curve;Chromatography, High Pressure Liquid
8869767;Injections, Intravenous;Injections, Subcutaneous
8881693
8911887;Blood Pressure;Cross-Over Studies;Heart Rate;Administration, Oral
8925804
8926537;Diet
8929750;Administration, Oral;Area Under Curve;Reference Values
8947977;Blood Pressure;Cross-Over Studies;Area Under Curve
8961058;APACHE
8971132;Magnetic Resonance Spectroscopy;Mass Spectrometry;Chromatography, High Pressure Liquid;Chromatography, Thin Layer;In Vitro Techniques
8988067;Cross-Over Studies;Administration, Oral;Reference Values;Chromatography, High Pressure Liquid
9002010
9075501
9091822
9114910;Administration, Oral
9129557;Area Under Curve;Electrocardiography;Reference Values
9147710;Cross-Over Studies;Double-Blind Method;Area Under Curve;Chromatography, High Pressure Liquid;Spectrophotometry, Ultraviolet
9153347;Cross-Over Studies;Fasting;Administration, Oral
9159606;Blood Coagulation Tests
9174684;Blood Pressure;Cross-Over Studies;Heart Rate;Injections, Intravenous;Administration, Oral
9217843
9218932;Cross-Over Studies
9220063;Diagnosis, Differential
9234037;Breath Tests;Surveys and Questionnaires
9248771;Area Under Curve;Electrocardiography;Chromatography, High Pressure Liquid
9315022
9357093;Area Under Curve;Metabolic Clearance Rate
9385040;Cross-Over Studies;Administration, Oral;Area Under Curve;Chromatography, High Pressure Liquid
9399621;Tomography, X-Ray Computed
9414309;Administration, Oral;Treatment Outcome;Evaluation Studies as Topic
9431825;Cross-Over Studies;Administration, Oral;Area Under Curve;Chromatography, Gas;Infusions, Intravenous
9469677;Area Under Curve
9518947
9545149;Cross-Over Studies;Fasting;Administration, Oral;Drug Evaluation
9555149
9562133;Cross-Over Studies;Area Under Curve
9562227;Cross-Over Studies;Confidence Intervals;Analysis of Variance;Administration, Oral;Area Under Curve;Reference Values;Chromatography, Gas
9566982;Diet
9578182;Area Under Curve
9585793;Cross-Over Studies;Area Under Curve;Reference Values
9591935;Blood Pressure;Cross-Over Studies;Heart Rate
9604823;Constriction;Retrospective Studies;Drug Monitoring
9609412;Cross-Over Studies;Infusions, Intravenous;Drug Monitoring
9620100;Double-Blind Method;Pain Measurement
9620116;Injections, Intravenous
9625273;Cross-Over Studies
9633781
9660036;Area Under Curve
9696960;Administration, Oral
9706183;Analysis of Variance;Prothrombin Time
9738088
9757152;Cross-Over Studies;Drug Administration Schedule;Area Under Curve
9768962
9793589;Cross-Over Studies;Fasting;Administration, Oral;Area Under Curve
9793622;Reproducibility of Results;Fasting;Area Under Curve;Spectrometry, Fluorescence;Chromatography, High Pressure Liquid
9800751
9807978;Cross-Over Studies;Administration, Oral;Area Under Curve;Metabolic Clearance Rate;Chromatography, High Pressure Liquid;Infusions, Intravenous
9818297
9834039;Cross-Over Studies;Gas Chromatography-Mass Spectrometry;Area Under Curve;Reference Values
9840238;Cross-Over Studies;Prospective Studies;Intubation, Gastrointestinal;Chromatography, High Pressure Liquid;Infusions, Intravenous;Drug Monitoring
9871430;Cross-Over Studies;Reference Values
9882081;Cross-Over Studies
9924842
10030529
10073324;Area Under Curve
10082701
10086430
10096255;Cross-Over Studies;Reference Values
10096258;Cross-Over Studies;Area Under Curve;Reference Values
10102468;Diet
10192596;Food Analysis;Diet;Chromatography, High Pressure Liquid
10217316;Area Under Curve;Prothrombin Time;Chromatography, High Pressure Liquid
10220126
10243361
10332534
10350016;Cross-Over Studies;Gastric Acidity Determination
10365642;Cross-Over Studies;Reference Values
10375176;Analysis of Variance
10423213
10440622;Cross-Over Studies
10456490;Cross-Over Studies;Chromatography, High Pressure Liquid
10456492;Electrocardiography;Chromatography, High Pressure Liquid
10460065;Cross-Over Studies;Gas Chromatography-Mass Spectrometry;Reference Values
10460103;Cross-Over Studies;Regression Analysis;Fasting;Analysis of Variance;Statistics, Nonparametric;Chromatography, High Pressure Liquid
10471985;Chromatography, High Pressure Liquid
10510161;Cross-Over Studies;Double-Blind Method
10533874;Risk Factors
10546917;Single-Blind Method;Analysis of Variance;Drug Administration Schedule;Area Under Curve;Reference Values
10546919;Cross-Over Studies;Gas Chromatography-Mass Spectrometry;Analysis of Variance;Area Under Curve;Reference Values
10546925;Cross-Over Studies;Administration, Oral;Reference Values
10556183;International Normalized Ratio;Multivariate Analysis;Prospective Studies;Treatment Outcome;Drug Monitoring;Cohort Studies
10568341;Food Analysis;Diet
10578942;Treatment Outcome
10583025;Gas Chromatography-Mass Spectrometry;In Vitro Techniques
10594487
10606838;Cross-Over Studies;Area Under Curve;Chromatography, High Pressure Liquid
10610011;Fasting
10615351
10636361;Adverse Drug Reaction Reporting Systems;Treatment Outcome;Clinical Trials as Topic
10638471;Chromatography, High Pressure Liquid
10681341;Prospective Studies;Double-Blind Method;Area Under Curve;Electrocardiography;Treatment Outcome
10683008
10702883;Cross-Over Studies;Fasting;Administration, Oral;Area Under Curve
10706847
10740993
10741622;Blood Pressure;Heart Rate;Reference Values
10759694;Area Under Curve;Electrocardiography
10852634
10872652;Area Under Curve
10878206
10893655;Cross-Over Studies;Fasting;Analysis of Variance;Statistics, Nonparametric
10930711;Disease Models, Animal
10945313;Blood Pressure;Heart Rate;Area Under Curve;Reference Values
10968409;Diet
11002387
11009051;Cross-Over Studies;Logistic Models
11049012;Cross-Over Studies;Double-Blind Method;Area Under Curve
11061578;Cross-Over Studies;Gas Chromatography-Mass Spectrometry;Analysis of Variance;Drug Administration Schedule;Administration, Oral;Area Under Curve;Reference Values
11069440;Blood Pressure;Cross-Over Studies;Injections, Intravenous;Administration, Oral;Pulse
11073292
11079273;Cross-Over Studies;Administration, Oral
11103749;Cross-Over Studies;Administration, Oral;Area Under Curve
11108077
11117974;Adverse Drug Reaction Reporting Systems;Fatal Outcome
11144706
11161079;Bleeding Time
11161541;Cross-Over Studies;Prospective Studies;Area Under Curve
11180019
11180020
11180034;Cross-Over Studies;Administration, Oral
11185412;Cross-Over Studies
11194535;Reproducibility of Results;Diet;Nutrition Assessment
11203429
11206893
11214770;Cross-Over Studies;Area Under Curve
11214778;Blood Pressure;Cross-Over Studies;Heart Rate;Double-Blind Method;Area Under Curve;Chromatography, High Pressure Liquid
11231102
11257244;Cross-Over Studies
11269572;Cross-Over Studies;Area Under Curve
11276296;Treatment Outcome
11310527;International Normalized Ratio;Bleeding Time
11322025
11327742;Obesity;Prospective Studies;Administration, Oral
11347624
11352440;Cross-Over Studies;Analysis of Variance;Administration, Oral;Area Under Curve;Metabolic Clearance Rate
11356998;Food Analysis;Nutrition Assessment
11361052;Blood Pressure;Heart Rate;Analysis of Variance;Administration, Oral;Area Under Curve;Metabolic Clearance Rate
11365266
11376916;Double-Blind Method;Reaction Time
11410431
11426073
11454132;International Normalized Ratio
11474706
11477318;Cross-Over Studies;Area Under Curve;Chromatography, High Pressure Liquid
11481175
11501187
11524501
11554427;In Vitro Techniques
11558205
11570073
11673746;Cross-Over Studies;Area Under Curve
11675844;International Normalized Ratio
11693229;Obesity;Substance Abuse Detection
11718495;Cross-Over Studies;Electrophoresis, Capillary;Fasting;Administration, Oral;Area Under Curve
11728055
11728770
11740713;Drug Administration Schedule;Administration, Oral;Longitudinal Studies
11745911;Cross-Over Studies;Fasting;Injections, Intravenous;Analysis of Variance;Administration, Oral
11753267;Cross-Over Studies;Double-Blind Method;Area Under Curve;Mass Spectrometry;Chromatography, Liquid
11762562;Breath Tests
11763808;International Normalized Ratio;Diet
11791889;Cross-Over Studies
11797495
11823753;Double-Blind Method;Administration, Oral;Area Under Curve
11823754;Blood Pressure;Heart Rate;Area Under Curve;Calibration
11871046
11906584
11936572;Cross-Over Studies;Analysis of Variance;Area Under Curve;Statistics, Nonparametric
11953006
11956673;Cross-Over Studies;Chromatography, High Pressure Liquid
11959616;Cross-Over Studies
11966676
12014354;International Normalized Ratio
12040751
12087344;Drug Administration Schedule;Reference Values
12187697;Severity of Illness Index;Treatment Outcome
12362932;Cross-Over Studies;Chromatography, High Pressure Liquid
12391711
12393786
12394419;Surveys and Questionnaires
12404692;Analysis of Variance;Reaction Time;Chi-Square Distribution
12451428;Blood Pressure;Cross-Over Studies;Heart Rate;Administration, Oral;Area Under Curve
12452752;International Normalized Ratio
12463728;Cross-Over Studies;Fasting;Area Under Curve
12472986;Cross-Over Studies;Administration, Oral;Reference Values;Chromatography, High Pressure Liquid
12482227;Fatal Outcome
12495014;Sample Size;False Negative Reactions;Bacteriological Techniques
12503845
12520633
12545142;Cross-Over Studies;Drug Administration Schedule;Reference Values
12554137;Reference Standards;Reproducibility of Results;Gas Chromatography-Mass Spectrometry;Substance Abuse Detection
12580002;Immunoassay;Reproducibility of Results;False Negative Reactions;Drug Monitoring;False Positive Reactions
12580992;Cross-Over Studies;Analysis of Variance;Administration, Oral;Chromatography, High Pressure Liquid
12580993
12589390;Analysis of Variance
12618710;Angiography
12621384;Blood Pressure;Cross-Over Studies;Heart Rate;Administration, Oral;Area Under Curve;Reference Values;Chromatography, High Pressure Liquid
12636154
12649774
12672771;Risk;Controlled Clinical Trials as Topic;Randomized Controlled Trials as Topic
12677367
12680887;Cross-Over Studies;Fasting;Administration, Oral
12695337;Area Under Curve
12757117
12773074;International Normalized Ratio
12782911;Treatment Outcome
12811362;Area Under Curve
12818420;Risk Assessment;Fatal Outcome
12825970;International Normalized Ratio;Surveys and Questionnaires
12845387;Cross-Over Studies;Area Under Curve;Metabolic Clearance Rate
12891227;Area Under Curve;Chromatography, High Pressure Liquid
12906366;Reference Values
12908854;Cross-Over Studies;Body Weight;Double-Blind Method;Drug Administration Schedule;Administration, Oral;Area Under Curve
12915954;Cross-Over Studies;Heart Rate;Double-Blind Method;Administration, Oral;Area Under Curve
12921244;Cross-Over Studies;Administration, Oral;Area Under Curve
12940502;Reaction Time;Surveys and Questionnaires
12942422
12959294
12971031;Cross-Over Studies;Fasting
13309332
13358299
13359661
13811223
13855374
14088308
14100187
14132623
14172385;Medical Records
14214493
14254960
14280527
14498173
14567065;Blood Pressure;Colorimetry;In Vitro Techniques
14595580;Administration, Oral;Area Under Curve;Infusions, Intravenous
14612100;Cross-Over Studies
14616409;Cross-Over Studies;Administration, Oral;Area Under Curve
14616429;Cross-Over Studies;Administration, Oral
14629295
14653226;Cross-Over Studies;Fasting;Random Allocation
14663456;Area Under Curve;Metabolic Clearance Rate
14684645;International Normalized Ratio;Fatal Outcome
14713367
14717783;Regression Analysis;Drug Administration Schedule;Treatment Outcome
14725610;Cross-Over Studies
14742762;International Normalized Ratio
14749695;Administration, Oral;Area Under Curve;Reference Values;Infusions, Intravenous
14765835;Reference Values
14981197
15001969;Cross-Over Studies;Area Under Curve;Statistics, Nonparametric
15001970;Cross-Over Studies;Analysis of Variance;Area Under Curve
15025743;Cross-Over Studies
15025748
15060505;Blood Pressure;Cross-Over Studies;Heart Rate;Confidence Intervals;Double-Blind Method;Drug Administration Schedule;Risk Assessment;Area Under Curve;Sensitivity and Specificity
15060508;Analysis of Variance;Drug Administration Schedule;Administration, Oral;Area Under Curve;Perfusion;Sensitivity and Specificity
15089812;Cross-Over Studies;International Normalized Ratio;Analysis of Variance;Area Under Curve;Prothrombin Time
15098799;Cross-Over Studies;Area Under Curve
15121490;Cross-Over Studies;Multivariate Analysis;Prospective Studies;Diet;Administration, Oral;Observation;Logistic Models;Drug Monitoring;Case-Control Studies
15151167
15169710
15176651;Pilot Projects;False Positive Reactions
15179409;Confidence Intervals;Double-Blind Method;Area Under Curve
15186565
15206993;Cross-Over Studies
15223879
15229464;Area Under Curve;Metabolic Clearance Rate
15231565;International Normalized Ratio;Drug Stability
15238367;International Normalized Ratio;Area Under Curve
15292490
15307118;International Normalized Ratio
15329598;Cross-Over Studies;Spectrometry, Mass, Electrospray Ionization;Area Under Curve;Chromatography, High Pressure Liquid
15344253
15372129;Double-Blind Method;Area Under Curve;Chromatography, High Pressure Liquid
15449760;International Normalized Ratio
15470332;Cross-Over Studies;Area Under Curve
15506876;Analysis of Variance
15521566;Administration, Oral
15521893;Blood Pressure;Body Mass Index;Cross-Over Studies;Administration, Oral;Infusions, Intravenous
15536458;Chromatography, High Pressure Liquid
15581264;Cross-Over Studies;Administration, Oral;Area Under Curve;Infusions, Intravenous
15592321;Mass Spectrometry
15592332;Cross-Over Studies;Area Under Curve;Chromatography, High Pressure Liquid;Spectrophotometry, Ultraviolet
15608563
15635366;Blood Pressure
15655860
15673597;Area Under Curve;Chromatography, High Pressure Liquid;In Vitro Techniques;Spectrophotometry, Ultraviolet
15735611;Cross-Over Studies;Administration, Oral;Area Under Curve
15735617;Pilot Projects;Drug Administration Schedule;Area Under Curve;Clinical Trials, Phase I as Topic
15801937;Cross-Over Studies;International Normalized Ratio;Administration, Oral;Area Under Curve
15856409;Double-Blind Method;Area Under Curve;Treatment Outcome
15886802;International Normalized Ratio;Diet;Treatment Outcome
15900287;Drug Administration Schedule;Patient Selection
15900292
15901751;Cross-Over Studies;Area Under Curve;Chromatography, High Pressure Liquid
15903127;Area Under Curve;Blotting, Western
15983823;Blood Pressure;Cross-Over Studies;Heart Rate;Area Under Curve;Metabolic Clearance Rate
16062162
16100300
16116693;Drug Labeling;Reference Values
16120075;Cross-Over Studies
16122283;Administration, Oral;Intubation, Gastrointestinal
16133554
16203421
16221754;Drug Administration Schedule;Administration, Oral;Area Under Curve
16236039;Cross-Over Studies;Area Under Curve
16261361;Area Under Curve;Mass Spectrometry;Chromatography, High Pressure Liquid
16305592;Cross-Over Studies
16388930;Pilot Projects;Microdialysis;Administration, Oral
16412477;Cross-Over Studies;Reverse Transcriptase Polymerase Chain Reaction;Blotting, Western
16413247;Cross-Over Studies;Double-Blind Method;Area Under Curve;In Vitro Techniques
16416305;Cross-Over Studies;Analysis of Variance;Area Under Curve;Metabolic Clearance Rate;Chromatography, High Pressure Liquid
16428919;In Vitro Techniques
16484565;Blood Pressure;Pilot Projects;Double-Blind Method
16541194
16636327
16704760;Fluorescence Polarization Immunoassay;Immunoassay;Chromatography, Thin Layer;Drug Monitoring
16772772;International Normalized Ratio
16923466;Follow-Up Studies
16941417;International Normalized Ratio;Prospective Studies;Prothrombin Time;Statistics, Nonparametric
17016323
17018502;Diagnosis, Differential
17062300;Double-Blind Method;Follow-Up Studies;Administration, Oral;Treatment Outcome;Pain Measurement
17079360
17089110;Administration, Oral;Biometry;Cohort Studies
17546822
17641611
18226589;Tandem Mass Spectrometry;Reference Standards;Chemical Precipitation;Chromatography, Liquid;Calibration
20238900
20301621
21010059
21090491
22282124
25032445
8347123
12098842;Models, Biological
14255341
3677487;Metabolic Clearance Rate
